Publications by authors named "M Binnewies"

Myeloid cells in the tumor microenvironment (TME) can exist in immunosuppressive and immunostimulatory states that impede or promote antitumor immunity, respectively. Blocking suppressive myeloid cells or increasing stimulatory cells to enhance antitumor immune responses is an area of interest for therapeutic intervention. Triggering receptor expressed on myeloid cells-1 (TREM1) is a proinflammatory receptor that amplifies immune responses.

View Article and Find Full Text PDF

The development of immune checkpoint-based immunotherapies has been a major advancement in the treatment of cancer, with a subset of patients exhibiting durable clinical responses. A predictive biomarker for immunotherapy response is the preexisting T-cell infiltration in the tumor immune microenvironment (TIME). Bulk transcriptomics-based approaches can quantify the degree of T-cell infiltration using deconvolution methods and identify additional markers of inflamed/cold cancers at the bulk level.

View Article and Find Full Text PDF
Article Synopsis
  • The tumor immune microenvironment (TIME) is made up of various myeloid cells that show complex identities and behaviors, making it hard to understand their role in T-cell function and patient outcomes.
  • Researchers used single-cell RNA-sequencing to analyze mouse and human tumors, discovering that the diversity of monocyte-macrophage cells is influenced by both lineage and transcriptional changes during their development.
  • In mice, the transformation from monocytes to macrophages was linked to the presence of regulatory T cells (Tregs), while in human kidney cancer, variations in macrophage types and myeloid cell makeup correlated with the density of Tregs and the effectiveness of CD8+ T cells.
View Article and Find Full Text PDF

Converting checkpoint inhibitor (CPI)-resistant individuals to being responsive requires identifying suppressive mechanisms. We identify TREM2 tumor-associated macrophages (TAMs) as being correlated with exhausted CD8 tumor-infiltrating lymphocytes (TILs) in mouse syngeneic tumor models and human solid tumors of multiple histological types. Fc domain-enhanced anti-TREM2 monoclonal antibody (mAb) therapy promotes anti-tumor immunity by elimination and modulation of TAM populations, which leads to enhanced CD8 TIL infiltration and effector function.

View Article and Find Full Text PDF

Generation of tumor-infiltrating lymphocytes begins when tumor antigens reach the lymph node (LN) to stimulate T cells, yet we know little of how tumor material is disseminated among the large variety of antigen-presenting dendritic cell (DC) subsets in the LN. Here, we demonstrate that tumor proteins are carried to the LN within discrete vesicles inside DCs and are then transferred among DC subsets. A synapse is formed between interacting DCs and vesicle transfer takes place in the absence of free exosomes.

View Article and Find Full Text PDF